Targeting Arginase-II Protects Mice from High-fat-diet-induced Hepatic Steatosis Through Suppression of Macrophage Inflammation

Overview

Journal Sci Rep

Specialty Science

Date 2016 Feb 6

PMID 26846206

Citations 27

Authors

Chang Liu

Angana G Rajapakse

Erwin Riedo

Benoit Fellay

Marie-Claire Bernhard

Jean-Pierre Montani

Zhihong Yang

Xiu-Fen Ming

Affiliations

Soon will be listed here.

Abstract

Nonalcoholic fatty liver disease (NAFLD) associates with obesity and type 2 diabetes. Hypoactive AMP-activated protein kinase (AMPK), hyperactive mammalian target of rapamycin (mTOR) signaling, and macrophage-mediated inflammation are mechanistically linked to NAFLD. Studies investigating roles of arginase particularly the extrahepatic isoform arginase-II (Arg-II) in obesity-associated NAFLD showed contradictory results. Here we demonstrate that Arg-II(-/-) mice reveal decreased hepatic steatosis, macrophage infiltration, TNF-α and IL-6 as compared to the wild type (WT) littermates fed high fat diet (HFD). A higher AMPK activation (no difference in mTOR signaling), lower levels of lipogenic transcription factor SREBP-1c and activity/expression of lipogenic enzymes were observed in the Arg-II(-/-) mice liver. Moreover, release of TNF-α and IL-6 from bone marrow-derived macrophages (BMM) of Arg-II(-/-) mice is decreased as compared to WT-BMM. Conditioned medium from Arg-II(-/-)-BMM exhibits weaker activity to facilitate triglyceride synthesis paralleled with lower expression of SREBP-1c and SCD-1 and higher AMPK activation in hepatocytes as compared to that from WT-BMM. These effects of BMM conditioned medium can be neutralized by neutralizing antibodies against TNF-α and IL-6. Thus, Arg-II-expressing macrophages facilitate diet-induced NAFLD through TNF-α and IL-6 in obesity.

Citing Articles

Pathophysiology of Arginases in Cancer and Efforts in Their Pharmacological Inhibition.

Marzeta-Assas P, Jacenik D, Zaslona Z Int J Mol Sci. 2024; 25(18).

PMID: 39337272 PMC: 11431790. DOI: 10.3390/ijms25189782.

Myeloid-derived growth factor alleviates non-alcoholic fatty liver disease alleviates in a manner involving IKKβ/NF-κB signaling.

Ding Y, Xu X, Meng B, Wang L, Zhu B, Guo B Cell Death Dis. 2023; 14(6):376.

PMID: 37365185 PMC: 10293205. DOI: 10.1038/s41419-023-05904-y.

Targeting macrophagic 17-HSD7 by fenretinide for the treatment of nonalcoholic fatty liver disease.

Dong X, Feng Y, Xu D, Zhang M, Wen X, Zhao W Acta Pharm Sin B. 2023; 13(1):142-156.

PMID: 36815031 PMC: 9939369. DOI: 10.1016/j.apsb.2022.04.003.

Loss of Lkb1 in CD11c myeloid cells protects mice from diet-induced obesity while enhancing glucose intolerance and IL-17/IFN-γ imbalance.

Sun Y, Wang B, Hu Q, Zhang H, Lai X, Wang T Cell Mol Life Sci. 2023; 80(3):63.

PMID: 36781473 PMC: 9925521. DOI: 10.1007/s00018-023-04707-w.

Arginase: Biological and Therapeutic Implications in Diabetes Mellitus and Its Complications.

Ren Y, Li Z, Li W, Fan X, Han F, Huang Y Oxid Med Cell Longev. 2022; 2022:2419412.

PMID: 36338341 PMC: 9629921. DOI: 10.1155/2022/2419412.

References

Yamauchi T, Kamon J, Minokoshi Y, Ito Y, Waki H, Uchida S . Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med. 2002; 8(11):1288-95. DOI: 10.1038/nm788. View

Patsouris D, Li P, Thapar D, Chapman J, Olefsky J, Neels J . Ablation of CD11c-positive cells normalizes insulin sensitivity in obese insulin resistant animals. Cell Metab. 2008; 8(4):301-9. PMC: 2630775. DOI: 10.1016/j.cmet.2008.08.015. View

Lama J, Bell R, Storey K . Glucose-6-phosphate dehydrogenase regulation in the hepatopancreas of the anoxia-tolerant marine mollusc, Littorina littorea. PeerJ. 2013; 1:e21. PMC: 3628605. DOI: 10.7717/peerj.21. View

Ramirez-Zacarias J, Castro-Munozledo F . Quantitation of adipose conversion and triglycerides by staining intracytoplasmic lipids with Oil red O. Histochemistry. 1992; 97(6):493-7. DOI: 10.1007/BF00316069. View

You H, Gao T, Cooper T, Morris Jr S, Awad A . Arginase inhibition mediates renal tissue protection in diabetic nephropathy by a nitric oxide synthase 3-dependent mechanism. Kidney Int. 2013; 84(6):1189-97. PMC: 3783645. DOI: 10.1038/ki.2013.215. View

Xiong Y, Yu Y, Montani J, Yang Z, Ming X . Arginase-II induces vascular smooth muscle cell senescence and apoptosis through p66Shc and p53 independently of its l-arginine ureahydrolase activity: implications for atherosclerotic plaque vulnerability. J Am Heart Assoc. 2013; 2(4):e000096. PMC: 3828809. DOI: 10.1161/JAHA.113.000096. View

Crombez E, Cederbaum S . Hyperargininemia due to liver arginase deficiency. Mol Genet Metab. 2005; 84(3):243-51. DOI: 10.1016/j.ymgme.2004.11.004. View

Ming X, Rajapakse A, Yepuri G, Xiong Y, Carvas J, Ruffieux J . Arginase II Promotes Macrophage Inflammatory Responses Through Mitochondrial Reactive Oxygen Species, Contributing to Insulin Resistance and Atherogenesis. J Am Heart Assoc. 2012; 1(4):e000992. PMC: 3487353. DOI: 10.1161/JAHA.112.000992. View

Zhang W, Baban B, Rojas M, Tofigh S, Virmani S, Patel C . Arginase activity mediates retinal inflammation in endotoxin-induced uveitis. Am J Pathol. 2009; 175(2):891-902. PMC: 2716983. DOI: 10.2353/ajpath.2009.081115. View

10.

Yap F, Craddock L, Yang J . Mechanism of AMPK suppression of LXR-dependent Srebp-1c transcription. Int J Biol Sci. 2011; 7(5):645-50. PMC: 3107472. DOI: 10.7150/ijbs.7.645. View

11.

Porstmann T, Santos C, Griffiths B, Cully M, Wu M, Leevers S . SREBP activity is regulated by mTORC1 and contributes to Akt-dependent cell growth. Cell Metab. 2008; 8(3):224-36. PMC: 2593919. DOI: 10.1016/j.cmet.2008.07.007. View

12.

Shi O, Morris Jr S, Zoghbi H, Porter C, OBrien W . Generation of a mouse model for arginase II deficiency by targeted disruption of the arginase II gene. Mol Cell Biol. 2001; 21(3):811-3. PMC: 86672. DOI: 10.1128/MCB.21.3.811-813.2001. View

13.

Dizikes G, Grody W, Kern R, Cederbaum S . Isolation of human liver arginase cDNA and demonstration of nonhomology between the two human arginase genes. Biochem Biophys Res Commun. 1986; 141(1):53-9. DOI: 10.1016/s0006-291x(86)80333-3. View

14.

Yang Z, Ming X . Functions of arginase isoforms in macrophage inflammatory responses: impact on cardiovascular diseases and metabolic disorders. Front Immunol. 2014; 5:533. PMC: 4209887. DOI: 10.3389/fimmu.2014.00533. View

15.

Obstfeld A, Sugaru E, Thearle M, Francisco A, Gayet C, Ginsberg H . C-C chemokine receptor 2 (CCR2) regulates the hepatic recruitment of myeloid cells that promote obesity-induced hepatic steatosis. Diabetes. 2010; 59(4):916-25. PMC: 2844839. DOI: 10.2337/db09-1403. View

16.

Brown M, Goldstein J . Selective versus total insulin resistance: a pathogenic paradox. Cell Metab. 2008; 7(2):95-6. DOI: 10.1016/j.cmet.2007.12.009. View

17.

Yamaguchi K, Yang L, McCall S, Huang J, Yu X, Pandey S . Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis. Hepatology. 2007; 45(6):1366-74. DOI: 10.1002/hep.21655. View

18.

Khamzina L, Veilleux A, Bergeron S, Marette A . Increased activation of the mammalian target of rapamycin pathway in liver and skeletal muscle of obese rats: possible involvement in obesity-linked insulin resistance. Endocrinology. 2004; 146(3):1473-81. DOI: 10.1210/en.2004-0921. View

19.

Li S, Brown M, Goldstein J . Bifurcation of insulin signaling pathway in rat liver: mTORC1 required for stimulation of lipogenesis, but not inhibition of gluconeogenesis. Proc Natl Acad Sci U S A. 2010; 107(8):3441-6. PMC: 2840492. DOI: 10.1073/pnas.0914798107. View

20.

Pende M, Kozma S, Jaquet M, Oorschot V, Burcelin R, Le Marchand-Brustel Y . Hypoinsulinaemia, glucose intolerance and diminished beta-cell size in S6K1-deficient mice. Nature. 2001; 408(6815):994-7. DOI: 10.1038/35050135. View